OR WAIT null SECS
The field of cancer immunotherapy, once the sole purview of immunology, has evolved toward the harnessing of newly described properties of ionizing radiation (IR). Cancer immunotherapy now includes the combination of established cytotoxic modalities with immune manipulations, as vaccines alone are unlikely to succeed at curing bulky, established tumors.
The field of cancer immunotherapy, once the sole purview of immunology, has evolved toward the harnessing of newly described properties of ionizing radiation (IR). Cancer immunotherapy now includes the combination of established cytotoxic modalities with immune manipulations, as vaccines alone are unlikely to succeed at curing bulky, established tumors. Combining chemotherapy with immunotherapy has shown promise, despite the fact that both are systemic modalities with overlapping effects.[2-4] In this regard, radiotherapy has a clear advantage, as its effects can be targeted to the primary tumor, converting the tumor itself into an “immunologic hub” ideally capable of subverting the immune defeat that has resulted in the clinical presentation of cancer. This approach is appealing since most immune impairment appears to occur at the tumor site.
Dr. Hodge and coauthors have elegantly reviewed this field. They summarize the available evidence with regard to the effects of IR on the different mediators of an immune response, and they discuss the initial promising results that have been achieved with the translation of preclinical experience to the clinic.
As a novel application for IR, a partnership with immunotherapy has opened exciting new investigational horizons. While many ongoing efforts are aimed at integrating immunologic strategies with traditional radiotherapy protocols, a conceptual shift in the investigational approach should be considered. Investigators need to determine how to best harness IR, a physical modality, to serve cancer immunotherapy.
In this novel role, IR optimization to enhance immunity takes priority over the classical aim of achieving successful cytotoxicity that translates into local control. Instead, radiation-induced cell death and its associated danger signals participate in a more global strategy to recruit the immune system to the primary tumor, achieving successful in situ immunization that translates into systemic, antimetastatic immune responses.[7-9] The traditional definition of the radiotherapy target will need to be reevaluated, as will all concepts of dose, fractionation, and schedule.
The type of radiation dose and fractionation used in the clinic to treat cancer has evolved empirically as the best compromise between optimal tumor killing and recovery from damage to the normal tissue included in the treatment field. It is likely that the very inflammatory response that could be valuable to immunotherapy is in fact avoided in the current clinical practice of cancer radiotherapy. Nevertheless, important information could be derived by studying cancer patients who are currently receiving standard radiation treatments.
For instance, as described in the authors’ review, the original findings from the Neefjes’ lab-that after radiotherapy, IR-specific peptides are generated that are potentially capable of recruiting an immune response-warrants an accurate clinical exploration. Since the antibody response to tumor antigens correlates with T-cell immunity, IgG responses against these antigens can be identified by applying the technique of seromics to detect antigens as being de novo or increasingly recognized following treatment. This form of immune-monitoring, which does not require expression of a specific HLA allele by the patient, could detect which single dose currently used in the clinic is most effective at generating IR-specific peptides (ie, radiosurgery-like fractions or fraction sizes used in more standard fractionation regimens).
The ideal target for combining IR with immunotherapy is also not yet known. If the primary tumor is to be investigated as an “immunologic hub,” how can one best counteract the immunosuppressive effects of radiation? Should margins of “normal” adjacent tissue be included to assure a vigorous inflammatory response? In addition, should the draining lymph nodes be included in the radiation field? While IR could eliminate immunosupressive cell populations, this effect may not be a general rule. Breast cancer–specific immune profiles of draining nodes differ among patients and have been revealed to be robust, independent prognostic factors, thus favoring a more cautious and individualized approach, particularly if combined with immunotherapy.
Finally, it remains unknown when during its clinical course it is best to test the combination of IR and immunotherapy on a specific cancer. Ideally, an intervention earlier in the course of the disease would be expected to provide the best chance for success. From the point of view of immune surveillance, an intervention at the equilibrium phase-before the tumor coopts the immune system to enhance growth and angiogenesis-would be ideal, suggesting that testing in the adjuvant setting of radiotherapy is appropriate.
Conversely, preliminary data suggest that a lower degree of tumor response to radiotherapy may correspond to a favorable plasticity of the tumor to induce relevant signal transduction pathways that are crucial to immune system responses. For instance, IR induction of interferon-gamma influences antitumor immunity through a multiplicity of signal transduction pathways that involve MHC class I expression, induction of adhesion molecules like VCAM-1, and chemokines required for effector T-cell trafficking. These processes are consistently associated with intracellular signaling by STAT1. Since increased STAT1 expression is associated with a radioresistant phenotype, would carriers of recurrent tumors after radiation therapy be the best candidate for reirradiation with immunotherapy?
In summary, the review by Hodge et al calls for more collaboration between radiobiologists and cancer immunologists, while it encourages clinicians to recognize the fundamental role of the immune system in cancer and cancer therapies, and to revisit the field of radiation oncology with an open mind.
1. Bhardwaj N: Harnessing the immune system to treat cancer. J Clin Invest 117:1130-1136, 2007.
2. Emens LA, Machiels JP, Reilly RT, et al: Chemotherapy: Friend or foe to cancer vaccines? Curr Opin Mol Ther 3:77-84, 2001.
3. Emens LA, Jaffee EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-8064, 2005.
4. Gabrilovich DI: Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited. Lancet Oncol 8:2-3, 2007.
5. Demaria S, Formenti SC: Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 83:819-825, 2007.
6. Demaria S, Bhardwaj N, McBride WH, et al: Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63:655-666, 2005.
7. Apetoh L, Ghiringhelli F, Tesniere A, et al: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059, 2007.
8. Chakravarty PK, Guha C, Alfieri A, et al: Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: Its implication in designing a vaccination strategy. Oncology 70:245-254, 2006.
9. Demaria S, Ng B, Devitt ML, et al: Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58:862-870, 2004.
10. Reits EA, Hodge JW, Herberts CA, et al: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259-1271, 2006.
11. Suzuki H, Graziano DF, McKolanis J, et al: T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res 11:1521-1526, 2005.
12. Tsai CS, Chen FH, Wang CC, et al: Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys 68:499-507, 2007.
13. Kohrt HE, Nouri N, Nowels K, et al: Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2:e284, 2005.
14. Lugade AA, Sorensen EW, Gerber SA, et al: Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180:3132-3139, 2008.
15. Khodarev NN, Beckett M, Labay E, et al: STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 101:1714-1719, 2004.